Multicenter double-blind randomized clinical trial assessing efficacy and safety of exenatide in the treatment of hypothalamic obesity after craniopharyngioma therapy.
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Exenatide (Primary)
- Indications Hypothalamic disorders; Obesity
- Focus Therapeutic Use
- Acronyms CRANIOEXE
- 30 Mar 2024 Primary endpoint has not been met. (mean change in body weight at week 26 in the intention-to-treat population)
- 30 Mar 2024 Results published in the European Journal of Endocrinology
- 27 Jan 2019 Status changed from recruiting to completed.